Overview

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.
Phase:
Phase 2
Details
Lead Sponsor:
Repligen Corporation